Ozempic vs Wegovy vs Mounjaro vs Zepbound: Differences, Evidence, Safety and Access (2026)

By Dr. Frank Yap, MD, One Day Media Network · Published 2026-10-04 · Last updated 2026-10-04 · Reading time about 12 minutes

Quick Answer

Ozempic and Wegovy are the same drug (semaglutide); Mounjaro and Zepbound are the same drug (tirzepatide). Ozempic and Mounjaro are labeled for type 2 diabetes, while Wegovy and Zepbound are labeled for weight management. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. The right choice depends on diagnosis, coverage, tolerability and other conditions.

Are Ozempic, Wegovy, Mounjaro and Zepbound different drugs?

There are two active ingredients, each sold under two brand names. Semaglutide (Novo Nordisk) is sold as Ozempic and Wegovy. Tirzepatide (Eli Lilly) is sold as Mounjaro and Zepbound. The brand pairs share a molecule but differ in labeled indication, maximum dose, pen design and often insurance coverage.

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors, which is why it is called a dual agonist. Whether the added GIP activity fully explains tirzepatide's larger average effect is still debated, and the trial data below show the outcome difference rather than prove the mechanism.

How do the four compare side by side?

The table summarizes US labeling and headline trial results as of October 2026. Always confirm current labeling in the official prescribing information, because indications and doses are updated over time.

Ozempic
Active ingredientSemaglutide
ManufacturerNovo Nordisk
Receptor actionGLP-1
Core US indicationType 2 diabetes
Other labeled usesLower major cardiovascular events in T2D with heart disease; slow kidney disease progression in T2D with CKD
DosingOnce weekly injection
Maximum standard weekly dose2 mg
Pivotal weight-loss resultNot the labeled use; lower doses than Wegovy
Wegovy
Active ingredientSemaglutide
ManufacturerNovo Nordisk
Receptor actionGLP-1
Core US indicationChronic weight management
Other labeled usesLower major cardiovascular events in adults with obesity and established heart disease; MASH with moderate to advanced fibrosis
DosingOnce weekly injection (a daily Wegovy pill also exists)
Maximum standard weekly dose2.4 mg
Pivotal weight-loss resultAbout 14.9% at 68 weeks (STEP 1)
Mounjaro
Active ingredientTirzepatide
ManufacturerEli Lilly
Receptor actionGIP and GLP-1
Core US indicationType 2 diabetes
Other labeled usesNone beyond glycemic control at the time of writing
DosingOnce weekly injection
Maximum standard weekly dose15 mg
Pivotal weight-loss resultNot the labeled use for weight
Zepbound
Active ingredientTirzepatide
ManufacturerEli Lilly
Receptor actionGIP and GLP-1
Core US indicationChronic weight management
Other labeled usesObstructive sleep apnea in adults with obesity
DosingOnce weekly injection
Maximum standard weekly dose15 mg
Pivotal weight-loss resultAbout 20.9% at 72 weeks on 15 mg (SURMOUNT-1)

Evidence tier for this table: CEBM Level 2 (individual randomized trials) for efficacy figures; regulatory facts come from FDA labeling. Figures are from different trials with different populations, so cross-trial comparison is indirect. The head-to-head trial is covered next.

Which produces more weight loss: semaglutide or tirzepatide?

Tirzepatide produced greater average weight loss than semaglutide in the only large head-to-head trial. In SURMOUNT-5, an open-label randomized trial in 751 adults with obesity or overweight plus a weight-related condition and no diabetes, average weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide (about 22.8 kg versus 15.0 kg). Waist circumference fell 18.4 cm versus 13.0 cm. Roughly 31.6% on tirzepatide lost at least 25% of body weight versus 16.1% on semaglutide.

Adverse-event rates were similar between groups, at about 77% for tirzepatide and 79% for semaglutide for at least one event. Women lost more than men in both arms, so the average understates what some individuals achieve and overstates it for others.

Trial Drug and dose Population Result CEBM level
STEP 1 (Wilding 2021) Semaglutide 2.4 mg weekly Obesity, no diabetes, 68 weeks About 14.9% weight loss vs 2.4% placebo Level 2 (RCT)
SURMOUNT-1 (Jastreboff 2022) Tirzepatide 5, 10, 15 mg weekly Obesity, no diabetes, 72 weeks 15.0% (5 mg) up to 20.9% (15 mg) vs 3.1% placebo Level 2 (RCT)
SURMOUNT-5 (Aronne 2025) Tirzepatide vs semaglutide, maximum tolerated dose 751 adults, obesity, no diabetes, 72 weeks, open-label 20.2% vs 13.7%; waist 18.4 vs 13.0 cm Level 2 (RCT, head-to-head)
OASIS 4 (oral semaglutide 25 mg daily) Wegovy pill Obesity or overweight, 64 weeks 16.6% with full adherence vs 2.7% placebo Level 2 (RCT)

Weight loss is not the only outcome that matters. Greater weight reduction tends to bring greater improvement in blood pressure, triglycerides and glycemic markers, but cardiovascular outcome evidence differs between the two molecules, as described below.

Which drug has evidence for the heart, kidneys, liver and sleep apnea?

Semaglutide has the longer record in hard cardiovascular outcomes; tirzepatide has a specific labeled sleep apnea indication. The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes. Semaglutide 2.4 mg lowered major adverse cardiovascular events by about 20% (hazard ratio 0.80) over a mean of roughly 40 months, which supported the Wegovy cardiovascular indication.

  • Kidney: Ozempic carries a US indication to slow kidney disease progression in people with type 2 diabetes and chronic kidney disease, based on the FLOW trial. CEBM Level 2.
  • Liver: Wegovy has US approval for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis, an accelerated approval that depends on confirmatory outcome data. CEBM Level 2, surrogate endpoint.
  • Sleep apnea: Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. CEBM Level 2.
  • Tirzepatide cardiovascular outcomes: Outcome data are accumulating but are less mature than the semaglutide record. Check current labeling for any update.

What are the side effects, and who should avoid these medicines?

Side effects are broadly similar across all four products because they share a drug class. The most common are nausea, vomiting, diarrhea, constipation and abdominal discomfort, usually worst during dose escalation and often easing later. Slow titration is the main strategy used to improve tolerability.

Less common and serious risks

  • Gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
  • Pancreatitis. Persistent severe abdominal pain, with or without vomiting, needs urgent assessment.
  • Dehydration from vomiting or diarrhea, which can injure the kidneys.
  • Delayed gastric emptying, with labeling advice to tell anesthesia teams about use before procedures because of aspiration risk.
  • Hypoglycemia, mainly when combined with insulin or sulfonylureas in people with diabetes.
  • Diabetic retinopathy complications in people with type 2 diabetes and existing retinopathy, which warrants eye monitoring when glucose falls quickly.
  • Tirzepatide can reduce the effectiveness of oral hormonal contraceptives; labeling advises a non-oral or added barrier method around initiation and each dose increase.

Boxed warning (all four products)

Semaglutide and tirzepatide products carry a boxed warning about thyroid C-cell tumors seen in rodents. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are also not used in pregnancy. Seek urgent care for a neck lump, trouble swallowing, persistent hoarseness, or severe abdominal pain.

Evidence tier: CEBM Level 2 for adverse-event rates from pivotal trials; labeling statements reflect regulatory review of the whole evidence base.

What happens to your weight if you stop?

Most people regain a substantial portion of lost weight after stopping, which is why these are generally treated as long-term therapies. In the STEP 1 extension, participants who stopped semaglutide regained about two thirds of their prior loss within a year. In SURMOUNT-4, adults who switched from tirzepatide to placebo regained about 14% of body weight while those who continued lost a further 5.5%. CEBM Level 2.

Lifestyle, resistance training and adequate protein intake are commonly discussed alongside treatment to help preserve lean mass, but whether any specific program prevents regain after stopping is not established by these trials.

Are there pill versions? Wegovy pill and Foundayo (orforglipron)

Yes. Two daily oral GLP-1 products for obesity are now FDA-approved in the US. The FDA approved the Wegovy pill (oral semaglutide 25 mg once daily) on December 22, 2025, based on the OASIS program and the SELECT trial, and it reached US pharmacies in early January 2026 (Novo Nordisk announcement). The FDA approved Lilly's Foundayo (orforglipron) on April 1, 2026, a small-molecule oral GLP-1 that can be taken at any time of day without food or water restrictions (Lilly announcement).

Product Form Trial weight loss (headline) Note
Wegovy pill Daily oral semaglutide 25 mg 16.6% with full adherence at 64 weeks (OASIS 4) Taken under specific fasting instructions per label
Foundayo (orforglipron) Daily oral small molecule About 12.4% at the highest dose in the ATTAIN program Any time of day, no food or water restrictions
Zepbound injection Weekly injection About 20.9% at 15 mg (SURMOUNT-1) Highest average loss among these options in trials

Evidence tier: CEBM Level 2 per product; the pills have not been compared head-to-head with injections in a randomized trial in this summary.

How much do they cost?

Prices vary widely by payer, dose and pharmacy, and they change often. In the US, list prices run roughly US$1,000 to US$1,350 per month, while manufacturer self-pay programs (NovoCare Pharmacy for semaglutide, LillyDirect for tirzepatide) were reported in 2026 at roughly US$200 to US$450 per month depending on product and dose. With qualifying commercial insurance, savings cards can lower copays substantially. Treat every figure here as a snapshot and confirm on the manufacturer or pharmacy site before deciding.

How do clinicians think about choosing between them?

The decision is driven by diagnosis, goals, coexisting conditions, tolerability and coverage, not brand preference. The questions below are the ones a prescriber is likely to work through. They are a discussion guide, not a recommendation.

Situation What tends to matter
Type 2 diabetes is the main problem Ozempic or Mounjaro are labeled for it; both also lower weight. Ozempic has labeled cardiovascular and kidney indications in T2D.
Obesity without diabetes, maximum weight reduction is the goal Tirzepatide (Zepbound) produced the larger average loss in head-to-head data.
Obesity with established heart disease Semaglutide (Wegovy) has randomized cardiovascular outcome data (SELECT) and a labeled indication.
Obstructive sleep apnea with obesity Zepbound has a labeled indication.
MASH with significant fibrosis Wegovy has a labeled accelerated-approval indication.
Needle avoidance Oral options exist (Wegovy pill, Foundayo) with lower average loss in trials.
Medullary thyroid cancer or MEN 2 history, pregnancy, pancreatitis history Typically contraindicated or requires specialist judgment for the whole class.
Cost or insurance restrictions Formulary status and self-pay programs often decide what is practical.

How can you use this article with Claude, ChatGPT and Gemini?

AI assistants are useful for preparing questions and organizing information, not for choosing a prescription. Do not paste identifying details, lab reports or full medical records into a general-purpose assistant. Describe your situation in general terms and always verify drug facts against the prescribing information.

Assistant Best use here Example prompt
Claude Structuring a clinic-visit question list; explaining trial design and limitations “Using the SURMOUNT-5 and SELECT trials, write ten questions I should ask my doctor about semaglutide vs tirzepatide for someone with obesity and high blood pressure.”
ChatGPT Plain-language summaries and comparison tables you can edit “Summarize the differences between Wegovy and Zepbound in a table for a non-medical reader, and flag where evidence is head-to-head vs cross-trial.”
Gemini Cross-checking against Google-indexed regulatory pages “List the current FDA-labeled indications for Ozempic, Wegovy, Mounjaro and Zepbound and cite the label sections.”


Ask any assistant to name its sources and the date of each, and treat unsourced numbers as unverified.

Frequently asked questions

Is Ozempic the same as Wegovy?

Both contain semaglutide and are made by Novo Nordisk. They differ in labeled use, dose range and pens. Ozempic (up to 2 mg weekly) is labeled for type 2 diabetes, while Wegovy (2.4 mg weekly) is labeled for chronic weight management and related indications. Using Ozempic for weight loss is off-label.

Is Mounjaro the same as Zepbound?

Both contain tirzepatide and are made by Eli Lilly. Mounjaro is labeled for type 2 diabetes. Zepbound is labeled for chronic weight management and for obstructive sleep apnea in adults with obesity. The doses overlap, with a top weekly dose of 15 mg for each.

Which works better for weight loss: semaglutide or tirzepatide?

In SURMOUNT-5, a head-to-head open-label randomized trial of 751 adults with obesity, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide at 72 weeks. Individual results vary, and the trial excluded people with type 2 diabetes, so results may differ in other groups.

Can Ozempic or Mounjaro be used for weight loss?

Clinicians sometimes prescribe them off-label for weight loss, but their approved indication is type 2 diabetes. Insurance often will not cover off-label use, and the weight-management brands (Wegovy, Zepbound) carry trial-tested weight-loss dosing and labeling. Any such decision belongs with a licensed prescriber.

Will I regain weight if I stop?

Most people regain a substantial part of the lost weight after stopping. In the STEP 1 extension, participants regained about two thirds of their prior loss within a year of stopping semaglutide. In SURMOUNT-4, people switched from tirzepatide to placebo regained weight, while those who continued kept losing.

What are the most common side effects?

Gastrointestinal effects dominate across all four: nausea, vomiting, diarrhea and constipation, mostly during dose escalation. Less common risks include gallbladder disease, pancreatitis and dehydration-related kidney injury. All four carry a boxed warning about thyroid C-cell tumors in rodents.

Is there a pill version?

Yes. The FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg) on December 22, 2025. Lilly's once-daily Foundayo (orforglipron) was approved on April 1, 2026. Both are separate products from the weekly injections compared here, with lower average weight loss in trials than tirzepatide injections.

References and sources

  1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. doi:10.1056/NEJMoa2032183
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. doi:10.1056/NEJMoa2206038
  3. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2416394. Summary: American College of Cardiology journal scan
  4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. doi:10.1056/NEJMoa2307563
  5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022.
  6. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024.
  7. Novo Nordisk. Wegovy pill approved in the US as first oral GLP-1 for weight management. 22 December 2025. novonordisk.com
  8. Eli Lilly. FDA approves Foundayo (orforglipron). April 2026. investor.lilly.com
  9. FDA prescribing information for Ozempic, Wegovy, Mounjaro and Zepbound via Drugs@FDA. Confirm current indications and doses here.

Evidence key (CEBM)

Level 1: systematic review of randomized trials. Level 2: individual randomized trial or strong observational study. Level 3: non-randomized cohort or case-control. Level 4: case series. Level 5: expert opinion or mechanism-based reasoning. Tiers in this article follow the Oxford CEBM scheme and describe study design, not how large or relevant the effect is for any one person.

Pricing, approvals and regional availability change frequently. This article was last updated on 4 October 2026 and will be revised on this same URL as new data and labeling changes appear. Always confirm current details with an official source and a licensed prescriber.

Related GLP-1 Guides

The purpose of this hub is not to turn every new molecule into a treatment recommendation. It is to make rapidly changing peptide science easier to understand. Continue exploring the GLP-1 evidence library:

Tools and Telehealth (Affiliate Links)

  • Virtual care: if you need a clinician to review your symptoms, labs or GLP-1 plan, The Wellness Company virtual care is one telehealth pathway. Availability, eligibility and prescribing decisions are determined by their licensed clinicians.
  • Strength training at home: resistance band sets support the resistance-training advice above.
  • Portion and protein tracking: a digital kitchen scale makes it easier to estimate protein per meal.

Weight Loss & Metabolic Health Collection (E-Shop)

Medical Disclaimer

This article is for educational purposes and does not provide individualized medical advice. Do not change, stop or combine prescription medicines based solely on information in this article. Protein targets, exercise programs and body-composition monitoring should be individualized, particularly for people who are older, frail, undernourished or living with kidney disease or other chronic conditions.

Comments

Post a Comment

Popular posts from this blog

Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?

Image
Updated October 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that addin...
Read more

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy. On this page Approval status at a glance Pills vs injections Retatrutide: what is and isn't known Safety, side effects and compounding risks Evidence grades (CEBM) Using this hub with AI assistants FAQ Disclosures & sources 1. Approval ...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive re...
Read more

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

Image
Last reviewed: October 17, 2026. This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are in US dollars and are subject to change. Manufacturer savings programs have eligibility rules and may expire. The cost of a GLP-1 medication in 2026 can range from under $200 per month for certain oral formulations or introductory self-pay offers to several hundred dollars per month for ongoing treatment. Insurance may lower the cost considerably, but coverage for obesity treatment is not guaranteed—even when a medication is medically appropriate. This guide compares Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (orforglipron), Ozempic, Mounjaro and other prescription options , with an emphasis on what patients may actually pay. Important: A manufacturer's advertised price is not necessarily your final pharmacy price. Confirm the exact product, prescribed dose, dispensing method, insurance benefit and savings-progra...
Read more

Retatrutide and Muscle Loss: What the Research Shows and How to Preserve Muscle (2026)

Image
Does retatrutide cause muscle loss? The available evidence suggests that retatrutide-associated weight loss includes a reduction in lean mass, as occurs with other effective obesity treatments. However, the available studies do not establish how much actual skeletal muscle an individual will lose, whether the loss affects muscle function, or how much can be prevented through nutrition and exercise. In a published Phase 2 body-composition substudy involving adults with type 2 diabetes, researchers observed substantial fat-mass reductions alongside reductions in lean mass. The results do not show that retatrutide uniquely damages muscle, but they also do not justify assuming that very large weight losses will preserve muscle automatically. The practical priority is to pursue fat loss while preserving strength, physical function, adequate nutrition, and as much useful muscle as possible . Evidence updated October 2026. This article is educational and is not a substitute for ind...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...
Read more

Telehealth Peptide Providers 2026: How to Compare Prescription GLP-1s, Other Peptides, Compounding, Clinical Oversight and Pharmacy Sources

Image
A practical 2026 guide to comparing online peptide and GLP-1 care, with a focus on prescription legitimacy, FDA approval, compounding, clinician oversight, pharmacy sourcing, cost and patient safety. Last updated: October 2, 2026 Scope of this guide: This article primarily examines the U.S. telehealth market because FDA approval and U.S. compounding rules are central to the current peptide landscape. Availability, prescribing rules and product registration differ substantially in other countries. Telehealth has changed how patients access peptide-based medicines. Instead of starting with a traditional clinic visit, patients can often complete an online health assessment, meet a clinician by video or messaging, receive a prescription when medically appropriate, and have medication delivered through a pharmacy. The problem is that the word “peptide” now covers very different categories of products. An FDA-approved prescripti...
Read more

Peptide Therapy in 2026: What the Evidence Says About BPC-157, TB-500, MOTS-c and More

Image
Updated: October 2026 | Editorial team: OneDayMD | Purpose: Evidence and safety education Peptides are increasingly promoted for faster injury recovery, muscle growth, fat loss, better skin, improved sexual function, sleep and “anti-aging.” Some peptide medicines have transformed modern care. Others are experimental compounds with promising laboratory findings but little reliable evidence in people. The word peptide describes a type of molecule. It is not a guarantee of safety, effectiveness, purity or regulatory approval. Insulin and semaglutide are peptides; so are unapproved compounds sold online as “research chemicals.” Their evidence, manufacturing standards and medical uses are not interchangeable. Key takeaways Approved peptide medicines are not the same as research peptides. Approved medicines have been evaluated for specific uses, doses and risks. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon remain investigat...
Read more

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: September 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection in...
Read more

Oral Wegovy vs Foundayo vs Weekly Injections: Which Is Best for Weight Loss in 2026?

Image
Last reviewed: October 17, 2026 The obesity-treatment landscape has changed significantly with the arrival of oral GLP-1 medicines. People who previously had to choose between weekly injections, daily lifestyle changes, and other weight-management treatments now have additional prescription options. Two important oral treatments are Wegovy tablets (semaglutide 25 mg) from Novo Nordisk and Foundayo (orforglipron) from Eli Lilly. Both are taken daily, but they contain different active ingredients and have different administration requirements. Weekly injections remain important alternatives. These include standard-dose Wegovy, higher-dose Wegovy HD in the United States, and tirzepatide sold as Zepbound for weight management in the United States. Which option is best depends on the amount of weight loss needed, convenience, tolerability, other medical conditions, cost, and treatment availability. This guide compares the evidence without assuming that results from separate cl...
Read more